Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target
Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target